|
|
 |
 |
| |
 Printable version |
The hand-foot syndrome – a frequent secondary manifestation in antineoplastic chemotherapy |
European Journal of Dermatology. Volume 16, Number 5, 494-9, September-October 2006, Review article
|
 Free Article
|
Author(s) : M Janusch, M Fischer, WCH Marsch, H-J Holzhausen, T Kegel, P Helmbold |
Summary : The hand-foot syndrome (HFS) (palmoplantar erythrodysesthesia) designates acute, painful erythemas of the palms and soles of the feet caused by antineoplastic chemotherapies. The most frequent trigger substances are 5-fluoruracil and its derivates. At maximum severity, the HFS is bullous to erosive or ulcerous in character. The pathogenesis has not yet been clarified. Histologically, the HFS is characterized by a toxic keratinocyte reaction. Furthermore, there is sub-basal edema with a tendency to bullae, dilated blood and lymph capillaries and usually only mild perivascular lymphocytic infiltration. Early recognition and delineation from other differential diagnoses is prerequisite to targeted management of the disease. Depending on the severity, HFS requires dose reduction, interruption or switch in the antineoplastic chemotherapy. |
Keywords : differential diagnosis, hand-foot syndrome, immunohistology, palmoplantar erythrodysesthesia, transmission electron microscopy |
|
